GRCE Valuation

Grace Therapeutics, Inc

Add to Watchlist

Advanced Chart

3.080

-0.12(-3.750%)1D

Overview
Forecast
Valuation
Earnings

GRCE Relative Valuation

GRCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRCE is overvalued; if below, it's undervalued.

Historical Valuation

Grace Therapeutics, Inc (GRCE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.42 is considered Fairly compared with the five-year average of -3.26. The fair price of Grace Therapeutics, Inc (GRCE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.08

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.63

P/B

Median3y

0.59

Median5y

0.59

-33.68

FCF Yield

Median3y

-37.41

Median5y

-37.41

Competitors Valuation Multiple

The average P/S ratio for GRCE's competitors is 5.25, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE) exhibits a P/S ratio of 0.40, which is -92.35% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GRCE.O

Grace Therapeutics, Inc

0.40

Average P/S: 5.25

42.59M